Results 141 to 150 of about 61,838 (257)

Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. [PDF]

Eurasian J Med, 2022
Kocak MN, Ates O, Hacımuftuoglu A, Ates I, Tekin E, Ceylan O, Okkay U.   +6 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine. [PDF]

BMC Cardiovasc Disord, 2021
Clausen MF, Rørth R, Torp-Pedersen C, Westergaard LM, Weeke PE, Gislason G, Køber L, Fosbøl E, Kristensen SL.   +8 more
europepmc   +1 more source

Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?

Movement Disorders, EarlyView.
Manon Auffret, Marc Vérin
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. [PDF]

Cureus, 2021
Khalil G, Khan FA, Jamal QM, Saleem A, Masroor H, Abbas K.   +5 more
europepmc   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas. [PDF]

Endocr Oncol
Mignone E, Jukes AK, Valentine R, Allison R, De Sousa SMC.   +4 more
europepmc   +1 more source

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. [PDF]

BMC Endocr Disord, 2021
Zou Y, Li D, Gu J, Chen S, Wen X, Dong J, Jiang X.   +6 more
europepmc   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source